BRPI0509386A - compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos - Google Patents

compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0509386A
BRPI0509386A BRPI0509386-4A BRPI0509386A BRPI0509386A BR PI0509386 A BRPI0509386 A BR PI0509386A BR PI0509386 A BRPI0509386 A BR PI0509386A BR PI0509386 A BRPI0509386 A BR PI0509386A
Authority
BR
Brazil
Prior art keywords
treatment
isothiazole
isoxazole
amine compounds
neurodegenerative disorders
Prior art date
Application number
BRPI0509386-4A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Lei Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509386A publication Critical patent/BRPI0509386A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS DE ISOXAZOL- E ISOTIAZOL-AMINA PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS". A presente invenção refere-se a compostos de fórmula I em que R¬ 1¬, R¬ 3¬, R¬ 5¬, R¬ 6¬, R¬ 7¬, X e Y são conforme definidos. Compostos de fórmula I têm atividade na inibição da produção de peptídeo A<225>. A invenção também refere-se a composições farmacêuticas e métodos de tratamento de doenças e distúrbios, por exemplo, distúrbios neurodegenerativos e/ou neurológicos, por exemplo, doença de Alzhemier, em um mamífero compreendendo compostos de Fórmula I.
BRPI0509386-4A 2004-04-01 2005-03-21 compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos BRPI0509386A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55890004P 2004-04-01 2004-04-01
PCT/IB2005/000792 WO2005095361A1 (en) 2004-04-01 2005-03-21 Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0509386A true BRPI0509386A (pt) 2007-09-18

Family

ID=34962006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509386-4A BRPI0509386A (pt) 2004-04-01 2005-03-21 compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos

Country Status (6)

Country Link
US (1) US7220865B2 (pt)
EP (1) EP1735288A1 (pt)
JP (1) JP2007530658A (pt)
BR (1) BRPI0509386A (pt)
CA (1) CA2562106A1 (pt)
WO (1) WO2005095361A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1730119T3 (pl) * 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
WO2007034326A2 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003064396A1 (en) * 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
CA2501803A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
CA2501799C (en) 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
JP2006525990A (ja) 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物

Also Published As

Publication number Publication date
JP2007530658A (ja) 2007-11-01
US20050222149A1 (en) 2005-10-06
WO2005095361A1 (en) 2005-10-13
EP1735288A1 (en) 2006-12-27
US7220865B2 (en) 2007-05-22
CA2562106A1 (en) 2005-10-13
WO2005095361A8 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
BR112012015714A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0509515A (pt) composto, formulação farmacêutica, uso de um composto método para tratamento de doenças, e, processo para a preparação de um composto
WO2007109107A3 (en) Atf4 as a therapeutic target in alzheimers disease and other neurological disorders
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
BRPI0509386A (pt) compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
BRPI0413349A (pt) compostos de oxazol para o tratamento de doenças neurodegenerativas
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
BRPI0605484A2 (pt) toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2137 DE 20/12/2011.